Clinical Outcomes of Chemo-Immunotherapy for Extensive Stage Small Cell Lung Cancer: A Real-World Single Centre Study in Portugal
DOI:
https://doi.org/10.20344/amp.22546Keywords:
Antibodies, Monoclonal, Humanized, Immune Checkpoint Inhibitors, Immunotherapy, Small Cell Lung Carcinoma/drug therapyAbstract
Small cell lung cancer (SCLC) is an aggressive type of lung cancer. Recent studies have provided a new hope by adding atezolizumab to the standard treatment of extensive disease SCLC (E-SCLC). The aim of our study was to evaluate the real-life performance of atezolizumab plus chemotherapy in extensive stage SCLC in a Portuguese setting. Data was collected on twenty patients (70% were male with a mean age of 66.9 years) in treatment at a tertiary hospital in Portugal with E-SCLC treated with chemotherapy and atezolizumab between July 2022 and February 2024. All patients received a carboplatin plus etoposide regimen in combination with atezolizumab. The overall response rate was 55% (95% CI: 31.5 – 76.9) and the disease control rate was 70% (95% CI: 45.7 – 88.1). The median overall survival (OS) and progression-free survival (PFS) was 9.7 (95% CI:5.08 – 14.32) and 7.17 (95% CI:3.28 – 11.05) months, respectively. In total, 13 (65%) patients experienced disease progression and 10 (50%) died during follow-up from events related to the disease. Patients with a performance status score ≥ 2 had lower PFS (p = 0.003) and OS (p = 0.001). To the best of our knowledge, this is the first real-world clinical study in Portugal to evaluate real life outcomes for this combination therapy.
Downloads
References
Ezzedine R, Canellas A, Naltet C, Wislez M, Azarian R, Seferian A, et al. Evaluation of real-life chemoimmunotherapy combination in patients with metastatic small cell lung carcinoma (SCLC): a multicentric case–control study. Cancers. 2023;15:4593. DOI: https://doi.org/10.3390/cancers15184593
Landre T, Chouahnia K, Des Guetz G, Duchemann B, Assié JB, Chouaïd C. First-line immune-checkpoint inhibitor plus chemotherapy versus chemotherapy alone for extensive-stage small-cell lung cancer: a meta-analysis. Ther Adv Med Oncol. 2020;12:1-8. DOI: https://doi.org/10.1177/1758835920977137
Liu S V, Reck M, Mansfield AS, Mok T, Scherpereel A, Reinmuth N, et al. Updated overall survival and pd-l1 subgroup analysis of patients with extensivestage small-cell lung cancer treated with atezolizumab, carboplatin, and etoposide (IMpower133). J Clin Oncol. 2021;39:619-30. DOI: https://doi.org/10.1200/JCO.20.01055
Horn L, Mansfield AS, Szczęsna A, Havel L, Krzakowski M, Hochmair MJ, et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med. 2018;379:2220-9. DOI: https://doi.org/10.1056/NEJMoa1809064
Falchero L, Guisier F, Darrason M, Boyer A, Dayen C, Cousin S, et al. Long-term effectiveness and treatment sequences in patients with extensive stage small cell lung cancer receiving atezolizumab plus chemotherapy: results of the IFCT-1905 CLINATEZO real-world study. Lung Cancer. 2023;185:1-8. DOI: https://doi.org/10.1016/j.lungcan.2023.107379
Kim SH, Jo EJ, Mok J, Lee K, Kim KU, Park HK, et al. Real-world evaluation of atezolizumab and etoposide-carboplatin as a first-line treatment for extensive-stage small cell lung cancer. Korean J Med. 2023;38:218-25. DOI: https://doi.org/10.3904/kjim.2022.361
Sagie S, Maixner N, Stemmer A, Lobachov A, Bar J, Urban D. Real-world evidence for immunotherapy in the first line setting in small cell lung cancer. Lung Cancer. 2022;172:136-41. DOI: https://doi.org/10.1016/j.lungcan.2022.08.015
Shiono A, Imai H, Wasamoto S, Tsuda T, Nagai Y, Minemura H, et al. Real-world data of atezolizumab plus carboplatin and etoposide in elderly patients with extensive-disease small-cell lung cancer. Cancer Med. 2023;12:73-83. DOI: https://doi.org/10.1002/cam4.4938
Xiu W, Huang Y, Li Y, Yu M, Gong Y. Comorbidities and mortality risk among extensive-stage small-cell lung cancer patients in mainland China: Impacts of hypertension, type 2 diabetes mellitus, and chronic hepatitis B virus infection. Anticancer Drugs. 2022;33:80-90. DOI: https://doi.org/10.1097/CAD.0000000000001133
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Acta Médica Portuguesa
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All the articles published in the AMP are open access and comply with the requirements of funding agencies or academic institutions. The AMP is governed by the terms of the Creative Commons ‘Attribution – Non-Commercial Use - (CC-BY-NC)’ license, regarding the use by third parties.
It is the author’s responsibility to obtain approval for the reproduction of figures, tables, etc. from other publications.
Upon acceptance of an article for publication, the authors will be asked to complete the ICMJE “Copyright Liability and Copyright Sharing Statement “(http://www.actamedicaportuguesa.com/info/AMP-NormasPublicacao.pdf) and the “Declaration of Potential Conflicts of Interest” (http:// www.icmje.org/conflicts-of-interest). An e-mail will be sent to the corresponding author to acknowledge receipt of the manuscript.
After publication, the authors are authorised to make their articles available in repositories of their institutions of origin, as long as they always mention where they were published and according to the Creative Commons license.
